IGC Pharma IGC

IGC Pharma, Inc. is a biopharmaceutical company dedicated to developing therapeutics for Alzheimer's disease and related central nervous system disorders. The company focuses on discovering and advancing drug candidates that target symptoms such as agitation and sleep disturbance as well as underlying disease mechanisms. Its lead product candidate IGC AD1 is currently in a Phase 2 clinical trial for agitation in Alzheimer's dementia. In addition to its pipeline IGC Pharma maintains a portfolio of preclinical assets and invests in artificial intelligence tools to improve drug discovery and clinical trial design. The firm also sells over the counter health and wellness products through its Vancouver Washington facilities. The company's research strategy combines scientific innovation with operational execution to advance its programs toward potential commercialization. IGC Pharma aims to build a portfolio of differentiated therapies that address both symptomatic needs and disease modifying mechanisms.

IGC Pharma generates revenue primarily from the sale of its over the counter product lines and from licensing or collaborative agreements related to its intellectual property. While the company does not yet have commercial sales of its drug candidates, revenue from product sales supports ongoing research and development activities. The firm may also receive milestone payments or royalties from partners who license its technologies. In fiscal 2025 the company reported that 2 customers each accounted for more than 10 percent of total sales indicating a concentration in its revenue base. These revenues help fund clinical trials manufacturing expenses and general administrative costs.

The company operates through the following segment.

• Life Sciences: This segment encompasses all research development and commercialization activities aimed at Alzheimer's disease and other CNS disorders. It includes the advancement of IGC AD1 through clinical trials, the preclinical development of candidates such as TGR 63 and IGF based molecules, and the exploration of additional compounds targeting tau pathology and metabolic pathways. The segment also leverages artificial intelligence to analyze clinical data, identify biomarkers, and optimize trial protocols for greater efficiency. In addition it manages the manufacture and distribution of over the counter health products through its Vancouver Washington facilities.

Within the competitive landscape of neuroscience therapeutics IGC Pharma positions itself as a specialized innovator with a focused pipeline and proprietary technology. Larger pharmaceutical companies such as Axsome Therapeutics Otsuka and Lundbeck represent direct competition for agitation treatments while numerous biotech firms pursue Alzheimer's disease modification. IGC Pharma's competitive advantages stem from its internal contract research organization which reduces trial costs its growing patent portfolio with 12 issued patents and 31 pending applications and its AI driven approach that aims to improve trial efficiency and enable personalized medicine. The company also benefits from a team of scientists with expertise in cannabinoid chemistry neuroinflammation and clinical trial design which supports its ability to advance multiple candidates simultaneously. Despite these strengths IGC Pharma faces challenges common to early stage biotechs including limited financial resources and the inherent uncertainty of drug development outcomes.

The company's customer base consists of retail distributors online retailers and consumers who purchase its over the counter health products. Although the filing does not disclose specific customer names it notes that 2 customers each accounted for more than 10 percent of total sales in fiscal 2025 indicating a concentration among a few key partners. These customers likely include chains of pharmacies health food stores and online marketplaces that distribute the firm's wellness offerings. By maintaining relationships with these partners IGC Pharma seeks to expand its product reach while continuing to invest in its research pipeline.